Project Grant HT94252310976
Award Date
9/15/23
Completion Date
9/14/26
Dollars Obligated
$1.7M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
This Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $572,306 in funding to the University of Washington for a 3-year research project to develop "ENHANCED GENE THERAPY FOR DMD USING LARGER DYSTROPHINS AND LOWER VECTOR DOSES". The aim is to advance gene therapy approaches for treating Duchenne muscular dystrophy (DMD) by utilizing larger dystrophin gene constructs and reducing the required vector doses. The...
The University of Washington received a $617,221 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant funds research to advance the efficacy, longevity, and safety of gene editing therapies for Duchenne muscular dystrophy (DMD). The 2-year grant period runs from August 15, 2023 to August 14, 2025. As a leading research institution, the University of Washington has previously received federal funding to support a...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will fund research to develop improved gene replacement and editing therapies for Duchenne muscular dystrophy (DMD). The total award amount is $671,240 and the project period runs from January 22, 2025 to December 31, 2029. The key research objectives are to: 1) Refine technologies for expressing...
This federal Project Grant award of $345,664.00 from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) program, supports an advanced biomedical research initiative led by Royal Holloway University of London. The research project aims to develop an AAV-based microdystrophin gene therapy for Duchenne muscular dystrophy, with a focus on enhancing immune protection through capsid bioengineering. The award period spans from December 1, 2024 to November 30,...
This $539,400 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports vascular targeted therapy research for Duchenne muscular dystrophy. The grant was awarded to the Regents of the University of Minnesota, a major land-grant research university, to conduct this cutting-edge biomedical research project. The research aims to develop new treatments and advance scientific understanding of this neurological disorder, which...
This $1,464,751 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the University of California, Los Angeles (UCLA) to develop adeno-associated virus (AAV) vectors targeted to muscle and muscle stem cells. The goal is to improve the therapeutic efficacy and safety of treatments for Duchenne muscular dystrophy. The award period runs from September 1, 2024 to August 31, 2027. As the prime awardee, UCLA...
This $420,000 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Myogene Bio LLC, a woman-owned small biotechnology company, to evaluate the efficacy of CRISPR gene editing technology in treating Duchenne muscular dystrophy (DMD). The research aims to correlate CRISPR efficacy with functional outcomes in preclinical DMD models, building on the company's previous federal grant awards focused...
This $563,484.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Duke University to regulate skeletal muscle fibrosis in Duchenne muscular dystrophy. The two-year award, effective June 1, 2024 through May 31, 2026, will enable Duke University's research team to advance understanding and potential treatments for this debilitating neuromuscular disorder affecting military service members and...
The federal Project Grant award ID HT94252510342, totaling $405,341.00, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program. The award supports the use of proresolution and restorative pharmacology approaches for Duchenne muscular dystrophy (DMD) therapy at the Children's Research Institute, a non-profit pediatric research organization in Washington, D.C. The award will fund advanced biomedical research and development focused...
This federal Project Grant award of $513,653.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research by the University of Arkansas to develop self-delivering gene editors for the correction of Duchenne muscular dystrophy. The award period runs from August 15, 2024 to August 14, 2026, and aligns with the program's goal of transforming healthcare for military service members and the broader public through innovative...